These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 6417018)
21. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin A and immunoglobulin G antibody responses to alginates from Pseudomonas aeruginosa in patients with cystic fibrosis. Pedersen SS; Espersen F; Høiby N; Jensen T J Clin Microbiol; 1990 Apr; 28(4):747-55. PubMed ID: 2110181 [TBL] [Abstract][Full Text] [Related]
30. Alginate--its role in neutrophil responses and signal transduction towards mucoid Pseudomonas aeruginosa bacteria. König B; Friedl P; Pedersen SS; König W Int Arch Allergy Immunol; 1992; 99(1):98-106. PubMed ID: 1336422 [TBL] [Abstract][Full Text] [Related]
31. Antibodies to cell envelope proteins of Pseudomonas aeruginosa in cystic fibrosis patients. Fernandes PB; Kim C; Cundy KR; Haung NN Infect Immun; 1981 Aug; 33(2):527-32. PubMed ID: 6792080 [TBL] [Abstract][Full Text] [Related]
32. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients. Pier GB Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760 [TBL] [Abstract][Full Text] [Related]
33. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072 [TBL] [Abstract][Full Text] [Related]
34. The immunoevasive activities of Pseudomonas aeruginosa. Relevance for cystic fibrosis. Buret A; Cripps AW Am Rev Respir Dis; 1993 Sep; 148(3):793-805. PubMed ID: 8368651 [No Abstract] [Full Text] [Related]
35. Reactivity of monoclonal antibodies to Pseudomonas aeruginosa isolates from hospitalized adults and patients with cystic fibrosis. Torensma R; Fluit AC; Verhoef J Clin Infect Dis; 1994 Jul; 19(1):11-4. PubMed ID: 7948511 [TBL] [Abstract][Full Text] [Related]
36. Prospects for a mucoid exopolysaccharide vaccine for the prevention of infection due to mucoid strains of Pseudomonas aeruginosa. Baltimore RS Antibiot Chemother (1971); 1985; 36():147-56. PubMed ID: 3923912 [TBL] [Abstract][Full Text] [Related]
37. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. Meluleni GJ; Grout M; Evans DJ; Pier GB J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254 [TBL] [Abstract][Full Text] [Related]
38. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Pier GB; Small GJ; Warren HB Science; 1990 Aug; 249(4968):537-40. PubMed ID: 2116663 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Stiver HG; Zachidniak K; Speert DP Clin Invest Med; 1988 Aug; 11(4):247-52. PubMed ID: 2971496 [TBL] [Abstract][Full Text] [Related]